Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Michelle Woods

Physician Assistant Hickory, NC Physician Assistant

NPI 1982843637 CMS profile 11201205

311 9Th Avenue Dr Ne, Hickory, NC 28601

Open in the dashboard

General payments

$4,762

263 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michelle Woods of Hickory, NC is reported in the CMS Open Payments database as having received $4,762 across 263 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $83 4
2023 General $1,559 90
2022 General $1,879 109
2021 General $1,240 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Woods
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michelle Woods were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michelle Woods Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,240 $132 $37–$438 $132
2022 $1,879 $155 $48–$522 $149
2023 $1,559 $167 $52–$557 $160
2024 $83 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Lilly USA, LLC $635 43 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $440 28 payments
  3. Novo Nordisk Inc $399 27 payments
  4. Xeris Pharmaceuticals, Inc. $359 18 payments
  5. Medtronic, Inc. $318 7 payments
  6. AstraZeneca Pharmaceuticals LP $287 17 payments
  7. Amgen Inc. $244 13 payments
  8. Corcept Therapeutics $237 14 payments
  9. Sanofi-Aventis U.S. LLC $220 12 payments
  10. Abbott Laboratories $158 7 payments
  11. Other $1,464 77 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $4,746 261 payments
  2. Education $16 2 payments
Products named General payments · program years 2021–2024
  1. Kerendia $440 28 payments
  2. FARXIGA $287 17 payments
  3. Korlym $237 14 payments
  4. InPen $202 3 payments
  5. Repatha $190 10 payments
  6. JARDIANCE $185 13 payments
  7. Ozempic $178 12 payments
  8. RYBELSUS $165 11 payments
  9. RECORLEV $165 8 payments
  10. GVOKE PFS $151 8 payments
  11. Other $2,813 150 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,263

Median for Physician Assistant: 241

Drug cost

$1,038,140

Median for Physician Assistant: $4,110

Branded share of claims

87.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Korlym Mifepristone Brand 14 $432,368
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 142 $123,967
Ozempic Semaglutide Brand 88 $100,110
Tresiba Flextouch U-200 Insulin Degludec Brand 115 $86,647
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 57 $45,716
Jardiance Empagliflozin Brand 71 $42,723
Trulicity Dulaglutide Brand 35 $38,625
Farxiga Dapagliflozin Propanediol Brand 48 $33,019
Mounjaro Tirzepatide Brand 18 $28,165
Kerendia Finerenone Brand 23 $17,216

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RECORLEV
  • Xeris Pharmaceuticals, Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record